Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population: National Health and Nutrition Examination Survey 2005-2008

Journal of Cardiovascular Medicine

Volumn 12, Issue 10, 2011, Pages 714-722

  Christian, Jennifer B ^a   Bourgeois, Nancy E ^a   Lowe, Kimberly A ^b  

^a GLAXOSMITHKLINE   (United States)

^b EXPONENT INC   (United States)

Author keywords

dyslipidemic agent; high density lipoprotein cholesterol; National Health and Nutrition Examination Survey; triglycerides

Indexed keywords

APOLIPOPROTEIN B; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; UNITED STATES;

ADULT; AGED; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; DYSLIPIDEMIAS; FEMALE; HEALTH SURVEYS; HUMANS; HYPOLIPIDEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; NUTRITION SURVEYS; ODDS RATIO; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 80052620171     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328349c4e5     Document Type: Article

References (32)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004; 291:1238-1245. (Pubitemid 38541668)
2. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286:180-187. (Pubitemid 32640849)
3. Morrison A, Hokanson JE. The independent relationship between triglycerides and coronary heart disease. Vasc Health Risk Manag 2009; 5:89-95.
4. Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring study. J Lipid Res 1994; 35:871-882. (Pubitemid 24157238)
5. Weijenberg MP, Feskens EJ, Kromhout D. Age-related changes in total and high-density-lipoprotein cholesterol in elderly Dutch men. Am J Public Health 1996; 86:798-803. (Pubitemid 26192015)
6. Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 1977; 55:767-772. (Pubitemid 8090093)
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
8. Prevalence of abnormal lipid levels among youths-United States, 1999-2006. MMWR Morb Mortal Wkly Rep 2010; 59:29-33.
9. ALLHAT-LLT. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007.
10. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504. (Pubitemid 38477774)
11. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696. (Pubitemid 39140624)
12. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622. (Pubitemid 28248586)
13. HPSCG. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002; 360:7-22.
14. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435. (Pubitemid 40471450)
15. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study-a randomized controlled trial. JAMA 2005; 294:2437-2445. (Pubitemid 41627921)
16. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158. (Pubitemid 36398384)
17. Shepherd J, BlauwGJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-1630. (Pubitemid 35379733)
18. CDC. National Health and Nutrition Examination Survey: 2005-2006 Data Documentation, Codebook and Frequencies HDL-Cholesterol (HDLD), 2010. Available at http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/HDL-D.htm [accessed 12 July 2011].
19. Ansell BJ, Watson KE, Fogelman AM, et al. High-density lipoprotein function recent advances. J Am Coll Cardiol 2005; 46:1792-1798. (Pubitemid 41579798)
20. Aronow HD, Dutro MP, Kuznik A, Cwengros J. Prevalence of cardiovascular comorbidities and utilization of evidence-based treatment strategies among statin users in a Medicare and commercial health plan. Curr Med Res Opin 2009; 25:205-213.
21. Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of severe (500 to 2000 mg/dL) hypertriglyceridemia in United States adults. Am J Cardiol 2011; 107:891-897.
22. Ford ES, Li C, Zhao G, et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009; 169:572-578.
23. Schaefer JR, Schweer H, Ikewaki K, et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999; 144:177-184. (Pubitemid 29259979)
24. Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rhosignaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001; 107:1423-1432. (Pubitemid 32522036)
25. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338:86-93. (Pubitemid 28042271)
26. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. The Care Investigators. Circulation 1998; 98:2513-2519. (Pubitemid 29001188)
27. Kastelein JJ, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000; 86: 221-223. (Pubitemid 30410734)
28. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614-620. (Pubitemid 27143424)
29. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009. (Pubitemid 26338729)
30. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559. (Pubitemid 351831356)
31. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350:1505-1515. (Pubitemid 38477775)
32. NIH. Niacin plus statin to prevent vascular events, 2011. Available at www.clinicaltrials.gov [accessed 12 July 2011].